All-cause mortality and causes of death in the Swiss Hepatitis C Cohort Study

Maroussia Roelens[1*], Barbara Bertisch[1*], Darius Moradpour[2], Andreas Cerny[3], Nasser Semmo[4], Patrick Schmid[5], Beat Müllhaupt[6], Olivier Clerc[7], David Semela[8], Christoph Junker[9], Francesco Negro[10], Olivia Keiser[1], for the Swiss Hepatitis C Cohort Study

[1] Institute of Global Health, University of Geneva, Geneva, Switzerland

[2] Division of Gastroenterology and Hepatology, University Hospital Lausanne, Lausanne, Switzerland

[3] Fondazione Epatocentro Ticino, Lugano, Switzerland

[4] Department for BioMedical Research, Hepatology, University of Bern, Bern, Switzerland

[5] Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen

[6] Swiss Hepato-Pancreato-Biliary Center and Department of Gastroenterology and Hepatology, University Hospital, Zürich, Switzerland

[7] Department of Internal Medicine and Infectious Diseases, Pourtalès Hospital, Neuchâtel, Switzerland

[8] Division of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

[9] Swiss Federal Statistical Office, Section Population Health, Neuchâtel, Switzerland

[10] Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals Geneva, Geneva, Switzerland

Corresponding author: Maroussia Roelens, Institute of Global Health, University of Geneva, Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland.
Email: maroussia.roelens@unige.ch; Phone: +41 (0) 22 3790869

*These authors contributed equally to the current work

Keywords: hepatitis C, mortality, risk factors, cohort, Switzerland

5394 words, 3 figures, 3 tables

Conflict of interest: none

Financial support statement: This work was supported by the Swiss National Science Foundation (grant No. 163878).

Authors contributions: OK, BB and FN contributed to the design of the study. MR did the data analyses under the supervision of OK and BB. BB reviewed the causes of death. CJ performed the linkage between the SCCS decedents and the SFSO death registry. MR, BB and OK wrote the first draft of the paper. All authors contributed to the revision of the initial manuscript. All authors approved the final manuscript.

Abstract

Background & Aims: With the introduction of direct-acting antiviral agents (DAA), mortality rates and causes of death among persons with hepatitis C virus (HCV) infection are likely to change over time. However, the emergence of such trends may be delayed by the relatively slow progression of chronic hepatitis C. To date, detailed analyses of cause-specific mortality among HCV-infected persons over time remain limited.

Methods: We evaluated changes in causes of death among the Swiss Hepatitis C Cohort Study (SCCS) participants, from 2008 to 2016. We analysed risk factors for all-cause and cause-specific mortality, accounting for changes in treatment, fibrosis stage and use of injectable drugs over time. Mortality ascertainment was completed by linking lost-to-follow-up participants to the Swiss Federal Statistical Office (SFSO) death registry.

Results: We included 4,700 SCCS participants, of whom 478 died between 2008 and 2016. Linkage to the SFSO death registry substantially improved the information on causes of death (from 42% of deaths with unknown cause to 10% after linkage). Leading causes of death were liver failure (crude death rate 4.4/1000 person-years), liver cancer (3.4/1000 p-yrs) and non-liver cancer (2.8/1000 p-yrs), with an increasing proportion of cancer-related deaths over time. Cause-specific analysis showed that persons with sustained virologic response (SVR) were less at risk for liver-related mortality than those never treated or treated unsuccessfully.

Conclusions: Although the expected decrease in mortality is not yet observable, causes of death among HCV-infected persons evolved over time. With the progressive widening of guidelines for DAA use, liver-related mortality is expected to decline in the future. Continued monitoring of cause-specific mortality will remain important to assess the long-term effect of DAA and to design effective interventions.

Lay summary: Leading causes of death among persons with hepatitis C virus (HCV) infection in the Swiss Hepatitis C Cohort study evolved over the past years, with an increasing proportion of cancer-related deaths. The positive impact of new potent anti-HCV drugs on mortality among HCV-infected persons is not yet observable, due to both the slow progression of chronic hepatitis C and the progressive relaxation of guidelines for the use of those new drugs.

Background

Hepatitis C virus (HCV) infection is a leading cause of liver-related mortality [1, 2], responsible for about 399,000 deaths worldwide in 2016. With the introduction of potent direct-acting antiviral agents (DAA), the risk of morbidity and mortality for HCV infected persons has decreased substantially [3]. It is likely that causes of death are changing over time and with age, since HCV infected people may become increasingly at risk of dying from non-liver-related causes, including non- liver-related malignancies or cardiovascular diseases [4]. However, due to the slow progression of chronic hepatitis C, such trends may be slow to emerge. Some studies predict a rise in liver-related deaths to continue for another decade [5, 6], meanwhile the number of HCV-related deaths are stable or increasing in many settings [7].

Various studies have analysed mortality among HCV-infected persons. In the United States (US), several studies have shown that HCV-related deaths disproportionally affect persons born between 1945 and 1965 [8, 9]. Both a comparison between the Chronic Hepatitis Cohort Study and the official death certificates in the US [9], and a comparison between the Swiss Hepatitis C Cohort Study (SCCS) and the death certificates from the Swiss Federal Statistical Office (SFSO) [7] showed that under-reporting of HCV infection on death certificates is quite common. In both the US and Switzerland, HCV-related mortality increased significantly between the late 1990s and the early 2000s, whereas human immunodeficiency virus (HIV)-related mortality decreased, and hepatitis B virus (HBV)-related mortality remained relatively stable [7, 8]. In New South Wales, Australia, HCV notifications were linked to the death registry [1, 2]. When comparing mortality between HCV-infected persons and the general population, both liver-related and drug-related death rates were about 15-16 times higher in Australians with HCV. In HCV mono-infected persons, liver-related deaths increased considerably with older age, and drug-related death rates were higher in younger age groups [1, 2]. In this population, liver-related mortality remained stable between 1997 and 2006, and drug-related mortality was relatively constant between 2002 and 2006 [1, 2]. More recently, a study based on the US Veterans Affairs Hepatitis C Clinical Case Registry showed that, among HCV-infected patients treated with DAA,

108 successful treatment substantially reduced mortality, both in the presence and absence of advanced
109 liver disease [10, 11].
110
111 Nevertheless, few studies have analysed detailed patterns of cause-specific mortality among HCV-
112 infected persons. We therefore investigated the risk factors and time trends for all-cause and cause-
113 specific mortality among HCV-infected persons in the SCCS. We improved mortality ascertainment by
114 linking patients lost-to-follow-up to death certificates from the SFSO.

115 # Methods

116 **The Swiss Hepatitis C Cohort Study (SCCS)**

117 The SCCS is a prospective observational cohort study, established in 2000, that continuously enrols
118 adult patients aged ≥ 18 years in Switzerland. Only persons who are confirmed anti-HCV antibody-
119 positive are included [12]. Eight centres are involved, including all five university hospitals in
120 Switzerland (Basel, Bern, Geneva, Lausanne, Zurich), three large non-university hospitals (Lugano,
121 Neuchâtel and St. Gallen) and some affiliated centres. For all persons in the SCCS, various demographic,
122 psychosocial, clinical, laboratory and treatment data were collected via standardized questionnaires.
123 The questionnaires were completed by physicians or study nurses, during enrolment and annual
124 follow-up visits. The study was approved by all local ethics committees, and all persons provided
125 written informed consent. For deceased persons, the cause of death was coded according to the
126 International Statistical Classification of Diseases and Related Health Problems (ICD-10) [13].
127 Supplementary information was also provided to specify if the death was related to HCV infection or
128 due to an accident, a suicide or overdose/accidental poisoning.

129

130 **Eligibility criteria and definitions**

131 We included all persons enrolled before December 31st 2016 (until when data on causes of death were
132 compiled by the SFSO). We excluded those who died before January 1st 2008, because the new 13-digit
133 social security number (SSN), which was needed for the linkage, became available only in 2008.
134 Patients were lost-to-follow-up (LTFU) if they were not seen since August 2015 and not known to have
135 moved abroad or to have died. Sustained virologic response (SVR) was defined as an undetectable HCV
136 RNA ≥ 12 weeks after the end of antiviral treatment.

137

138 **Linkage with the SFSO death registry**

139 The SFSO has monitored causes of death in Switzerland since 1876. Causes of death are coded by the
140 ICD-10 code based on initial, consecutive and concomitant diseases listed on the SFSO death

141 certificate. To complete the SCCS information on mortality, deceased and LTFU persons in the SCCS
142 were linked to the SFSO death registry, by exact record linkage. The linkage was done for all persons
143 who were declared LTFU or dead in the SCCS between January 1st 2008 and December 31st 2016. We
144 used the 13-digit SSN and the date of birth for the linkage when the SSN was available. If the SSN was
145 not available, the linkage was based on the dates of birth and death.
146
147 **Coding and comparing causes of death**
148 We classified the main cause of death into mutually exclusive categories (liver cancer, liver failure, non-
149 liver cancer, cardiovascular, unnatural causes, other, unspecified) as described in Table 1. The "other"
150 category includes all deaths with a frequency below 30 persons. Unnatural causes of death include
151 suicide, overdose/accidental poisoning and accident.
152 For each deceased person in the SCCS, we retained one source of information to classify the cause
153 according to the following rules. For persons linked to the death registry, we preferentially selected
154 ICD-10 codes from the SFSO. When this information was not available, or when the SFSO provided less
155 specific information than the SCCS, we used the ICD-10 code from the SCCS. In case no ICD-10 code
156 was available from the SFSO or the SCCS, we used the supplementary information from the SCCS on
157 causes of death mentioned earlier, specifying if the death was physically related to HCV infection, or
158 due to an accident, a suicide or an overdose/accidental poisoning. All the deceased persons who could
159 not be classified following this procedure were defined "unspecified". Finally, the cause of death
160 classification was reviewed by an expert clinician who corrected misclassifications of complex cases
161 specific to HCV infection.
162 For the deceased persons linked to the SFSO death registry, we compared the main causes of death in
163 the SCCS and the SFSO. We measured the interrater agreement via the Kappa statistics in two ways
164 [14]: first by directly comparing the ICD-10 codes for the main cause of death, and then by using the
165 grouped causes of death using the groups in Table 1.
166
167 **Statistical analyses**

168 We calculated overall crude mortality rates and for different time periods, for both each cause of death
169 group and all-cause mortality. We also conducted survival analysis, for which follow-up time was
170 calculated from enrolment into the cohort or the starting date of the period of interest (baseline), to
171 the censoring date (which was either the date of death or the last known date of being alive). When
172 the dates of death in the SCCS and SFSO were different, we used the date of the SFSO.
173 We calculated crude cumulative incidences for each cause of death group, accounting for competing
174 risk (where each cause of death was a competing risk for the other causes), using the R *mstate* package
175 [15]. We then used Cox Proportional Hazard regression, including time-dependent covariables [14, 15],
176 to determine risk factors of mortality. We first analysed all-cause mortality, and then cause-specific
177 mortality, for each of the causes of death (except for "other" and "unspecified"). Analyses were
178 adjusted for sex, baseline age (as a continuous variable with restricted cubic splines [18]), fibrosis score
179 (F1 to F4), history of injection drug use (IDU) (ever, never), and treatment status (never treated, treated
180 with SVR, treated without SVR). For all-cause mortality, we also accounted for the treatment history
181 (never treated, ever treated and received DAA, ever treated but never received DAA). Due to the
182 limited number of deceased patients who received DAA, we could not add this co-variable in the cause-
183 specific analysis. To determine the fibrosis score, we combined the information from liver biopsies,
184 FibroScan™ analyses, and any reported cirrhosis during follow-up. Liver stiffness assessed by
185 FibroScan™ was converted to Metavir scores (F1: <7.5 kPa, F2: ≥ 7.5 to < 9.5 kPa, F3: ≥ 9.5 to < 12.5
186 kPa, and F4: ≥ 12.5 kPa) and reported cirrhosis was translated into a Metavir fibrosis score of 4. We
187 made no assumption on the possible evolution of fibrosis over time, and carried the values forward
188 until the next measurement or until the end of the study. We used multiple imputation by chained
189 equations (R *mice* package [19]) to impute missing values of time-dependent covariables (see details
190 in Appendix 1).
191 For sensitivity analysis, we recalculated the Cox Proportional Hazard models without multiple
192 imputation, excluding all the persons for whom information on treatment type and outcome, fibrosis
193 score, and history of IDU was incomplete at any time over the period of interest.

Results

Linkage SCCS – SFSO death registry

A total of 4,700 SCCS participants were followed between January 1st 2008 and December 31st 2016, with 471 of them reported to be deceased. The SSN was available for 66.0% (311 of 471) of persons and in the case where the SSN was not available (30.4% of persons, 143 of 471) the date of death was known. In addition, 245 of the followed persons were LTFU and 87.3% (n=214) of them had a SSN. Overall, 361 of the 471 deceased patients and 7 of the LTFU patients could be linked to the SFSO death registry. Figure 1 summarizes the flow chart of the linkage between the SCCS and the SFSO. Among the linked persons in the SCCS, the reported date of death was identical for 298 persons, was different for 54 (for 11 the difference was ± 1 day), and was missing for 16 persons (including the 7 persons LTFU who could be linked).

Characteristics of persons in the SCCS

After linkage between the SCCS and the SFSO death registry, date of death was known for 474 persons and remained unknown for 4 persons. The median duration of follow-up per patient was 6.5 years (IQR: 2.2 - 9.0). During a total of 26,114 person-years (pyrs) of follow-up, the overall mortality rate was 18.3/1,000 pyrs (95%CI: 16.7 - 20.0).

Table 2 shows the baseline characteristics of all the SCCS persons who were included and of deceased persons who could or could not be linked to the death registry. Persons were mostly male (61.7%), Swiss nationals (73.5%), and their median age at start of follow-up was 47.5 years (IQR: 40.6 - 55.1). The majority (54.9%) had a history of IDU, 38.8% had received antiviral treatment, and 17.6% were cirrhotic. Deceased persons who could or could not be linked to the death registry had similar characteristics (Table 2).

Comparison between causes of death in the SCCS and in the SFSO death registry

219 Of the 368 deceased persons who were linked to the death registry, the main cause of death was
220 available from both the SCCS and the SFSO for 249 persons (67,7%), and for 227 (91,1%) of these 249
221 persons ICD-10 codes were provided in the SCCS. When comparing the causes of death using the ICD-
222 10 codes, the Kappa statistic for interrater agreement was 0.14 (for 40 of 227 cases the codes were
223 identical). If we used the grouped causes of death, the Kappa statistics increased to 0.45 (in 138 of 249
224 cases the causes were identical), demonstrating that the agreement was weak for both approaches.
225
226 **Time trends in all-cause and cause-specific mortality among the persons in the SCCS**
227 Liver failure was the leading cause of death, with a crude death rate of 4.4/1000 pyrs (95% CI: 3.6 -
228 5.2), followed by liver cancer (3.4/1000 pyrs, CI 2.8 - 4.2), non-liver cancer (2.8/1000 pyrs, CI 2.2 - 3.4),
229 unnatural causes (2.5/1000 p-years, CI 2.0 - 3.1), other causes (2.3/1000 pyrs, CI 1.8 - 2.9), and
230 cardiovascular causes (1.3/1000 pyrs, CI 0.9 - 1.7). For 10% (n = 46) of the 478 deceased persons the
231 main cause of death was unknown.
232
233 Figure 2 shows the evolution of crude mortality rates for all-cause mortality, liver failure and liver
234 cancer mortality over the years. Similar curves for all the considered causes of death can be found in
235 Appendix 2. Before 2014, the leading cause of death was liver failure, followed by liver cancer and non-
236 liver cancer. In contrast, after 2014, when DAA became more widely available in Switzerland, liver
237 cancer became the leading cause of death, followed by liver failure and non-liver cancer.
238
239 Figure 3 shows the cumulative incidence of causes of death over time. The overall probability of dying
240 from any cause increased from 1.5% after one year of follow-up to 13.8% after eight years. While liver
241 failure remained the most common cause of death throughout the follow-up period, liver cancer
242 increased in relative proportion from year 6 onwards.
243
244 Table 3 shows the risk factors for all-cause and cause-specific mortality in the SCCS over the period
245 2008-2016.

246 For all-cause mortality, the risk of death was increased for men, older persons, those with a high
247 fibrosis stage and those with a history of IDU. Compared to persons who were never treated, the risk
248 of death was lower for treated persons who reached SVR after receiving interferon (IFN)-based
249 treatment (HR 0.33, 95% CI 0.24 - 0.45), and even slightly lower for treated persons who reached SVR
250 after receiving DAA (HR 0.23, 95% CI 0.08 - 0.63). In contrast, treated persons who did not achieve SVR
251 had a comparable risk of death to those who were never treated, irrespective of type of treatment.
252
253 Older persons and those with fibrosis score ≥ F3 were at higher risk of dying from liver failure than
254 younger persons and those with fibrosis score ≤ F2. Baseline treatment status was associated with
255 mortality due to liver failure, with a pronounced protective effect for treated persons with SVR, but no
256 reduction in risk for persons treated without SVR.
257
258 For liver cancer, the risk of death was higher for older persons, as reported previously by other studies
259 [20], and those with a high fibrosis stage. Having a history of IDU had little impact on liver cancer
260 mortality. Compared to never treated persons, the risk of dying decreased for treated persons with
261 SVR, but not for treated persons without SVR.
262
263 The risk of dying from non-liver cancer was higher for older persons than for younger persons.
264 Although there was no significant association between non-liver cancer mortality and treatment
265 status, nor with baseline fibrosis score, persons with a history of IDU were more at risk than persons
266 without a history of IDU.
267
268 Having ever used injectable drugs was associated with an increased risk of dying from unnatural
269 causes. In addition, persons aged 20 years were more at risk than persons aged 40 years or older, as
270 well as persons with a fibrosis score ≥ F3 compared to those with fibrosis score ≤ F2. There was no
271 association between unnatural causes of death and treatment status.
272

273 Results from the sensitivity analysis were similar to the main analysis for all-cause mortality, but there

274 were some notable differences for cause-specific mortality (Appendix 3).

275

276 # Discussion

277 Based on the SCCS data, we investigated time trends and risk factors of all-cause and cause-specific
278 mortality among HCV-infected persons in Switzerland. The linkage of the LTFU persons to the death
279 registry did not significantly increase the number of deaths. However the proportion of unknown
280 causes of death decreased substantially from 42% without linkage to 10% with linkage. The leading
281 causes of death changed over time, with a substantial increase in the proportion of deaths related to
282 liver cancer. Two factors probably explain this change: the risk of dying from liver disease increased as
283 people became older; and ascertainment of cause of death may have improved over time. Indeed, the
284 proportion of unspecified causes of death decreased from 13% in 2008-2013 to 4% in 2014-2016,
285 reflecting the better linkage in the latter years (92% of deceased persons could be linked in 2014-2016,
286 compared to 67% in 2008-2013).
287
288 Similarly to other studies [7], we found that mortality remained stable among HCV-infected persons in
289 Switzerland over the past few years. The expected decrease in mortality due to DAA is therefore not
290 occurring, or more probably not yet observable. The risk of death was lower for women, younger
291 persons, persons with lower fibrosis score, persons without a history of IDU, and treated persons who
292 reached SVR, with a first indication of a more positive effect with DAA compared to IFN-based
293 treatments. However, in contrast to some other studies, we found little evidence that being treated
294 with subsequent treatment failure had a protective effect compared to remaining untreated [19, 20].
295
296 For both liver failure and liver cancer, the risk of dying was significantly associated with treatment,
297 with a lower risk for treated persons with SVR than for treated persons without SVR or for untreated
298 persons. As data for wider use of DAA was only available for three years (2014 - 2016), we were not
299 able to evaluate the difference between successful IFN treatment and successful DAA treatment with
300 respect to liver-related mortality. Furthermore, in the early DAA era, the reimbursement of DAA by
301 health insurances was limited to persons with advanced fibrosis (Metavir stages F3 or F4). By mid-
302 2016, patients with Metavir score F2 were also treated [21, 22]. The limitation based on fibrosis stage

303 was relaxed progressively between July and October 2017, when all patients were treated, although
304 the prescription of DAA remained restricted to specialists.
305
306 Having a history of IDU was an important risk factor for death from non-liver cancer and unnatural
307 causes of death, explained by the inclusion of overdose/accidental poisoning in this category. Persons
308 who inject drugs (PWID) are a key subgroup of HCV-infected persons in Switzerland and other high-
309 income countries, where the majority of HCV infections occurred via injection of drugs [23, 24].
310 Despite the implementation of the four-pillar strategy [27], a national drug policy in Switzerland since
311 1994, additional obstacles exist for HCV treatment among PWID both from treatment providers and
312 from patients [27]. This results in some HCV-infected PWID entered care relatively late, at an advanced
313 fibrosis stage. The proportion of infected PWID who received anti-HCV treatments increased only
314 slightly from 51% in the years 2008-2013 to 58% in the years 2014-2016. The delay in treatment
315 initiation probably decreased, and even PWID who enter care late are more likely to reach favourable
316 outcomes with DAA. However, persons with a history of IDU now have a higher risk of dying from non-
317 liver cancer, potentially related to their addiction and to additional risk factors that are common among
318 PWID, such as smoking or excessive alcohol consumption.
319
320 Differences between causes of death reported in the SFSO death registry and the SCCS can be partly
321 explained by different coding practices. Detailed analysis of the discrepant entries revealed that for
322 19% of cases where the cause of death was coded as “other” in the SCCS, it was coded as “non-liver
323 cancer”, “unnatural cause”, or “cardiovascular disease” in the SFSO. The main focus of the SCCS was
324 likely to identify all HCV-related deaths, and there was less emphasis to record the exact cause of
325 death. For 21% of SCCS entries, cause of death was “liver failure” in one dataset and “liver cancer” in
326 the other, two causes that are relatively similar. Overall, clear discrepancies in the causes of death
327 recorded in the SCCS and the SFSO existed in only 21% of cases (Appendix 4).
328

329 To our knowledge, this is one of the first studies investigating detailed risk factors and time trends of
330 cause-specific mortality among HCV-infected persons. Due to the linkage with the death registry, we
331 significantly improved information on causes of death. By accounting for competing risks, by including
332 age as a continuous covariate (and not categorizing it arbitrarily), and by adjusting models for time-
333 dependent covariables, we could improve the accuracy of our analysis.
334 A limitation of this study was the unavailability of complete data relating to fibrosis stage evolution.
335 Due to this, we made no assumption on the evolution of fibrosis over time, and used multiple
336 imputation to impute missing values, which may compromise the robustness of our analysis. We did a
337 sensitivity analysis, using complete cases only. In this analysis, the number of persons for the cause-
338 specific analysis was relatively limited and results may therefore be less reliable.
339
340 In conclusion, although mortality did not, or did not yet decrease with DAA, we found that causes of
341 death changed over time. With the wider use of DAA, irrespective of fibrosis stage, it is likely that liver-
342 related mortality will continue to decline in the future. Continuous monitoring of mortality and causes
343 of death will therefore remain important to evaluate the long-term effect of DAA and to develop
344 effective interventions.

Acknowledgments

The Swiss Hepatitis C Cohort Study group comprises Francesco Negro, Laurent Kaiser (Geneva); Markus Heim, Hans Hirsch (Basel); Nasser Semmo, Franziska Suter (Bern); Darius Moradpour, Vincent Aubert (Lausanne); Hans H. Siegrist (La Chaux-de-Fonds); Andreas Cerny, Gladys Martinetti Lucchini (Lugano); Olivier Clerc (Neuchâtel); David Semela, Patrick Schmid, Günter Dollenmaier (St. Gallen); Beat Müllhaupt, Elsbeth Probst-Müller (Zürich); Pascal Benkert, Thomas Fabbro, Marielle Rutquist, Constantin Sluka (Basel Clinical Trial Unit).

We gratefully thank the SCCS study nurses: Ulrike Schnee-Lach (Basel); Kathrin Husi, Alice Gilg (Bern); Nicole Eicher, Fabio Cassano (Geneva); Adeline Mathieu, Maribelle Herranz (Lausanne); Claudia Dibartolomeo (Lugano); Marielle Grosjean (Neuchâtel); Patrizia Künzler-Heule, Roman Stillhard, Michelle Grahornig, Simone Kessler (St. Gallen); Barbara Brunner- Geissmann, Andrea Zumbühl (Zürich).

We thank the Swiss Federal Statistical Office for providing mortality data and for their support, which made this study possible.

We thank Danny Sheath and Rachel Esra for the editorial support.

365 # References

366

367 [1] J. Amin, M. G. Law, M. Bartlett, J. M. Kaldor, and G. J. Dore, 'Causes of death after
368 diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study',
369 *The Lancet*, vol. 368, no. 9539, pp. 938–945, Sep. 2006.

370 [2] S. R. Walter *et al.*, 'Trends in mortality after diagnosis of hepatitis B or C infection: 1992–
371 2006', *J. Hepatol.*, vol. 54, no. 5, pp. 879–886, May 2011.

372 [3] F. Carrat *et al.*, 'Clinical outcomes in patients with chronic hepatitis C after direct-acting
373 antiviral treatment: a prospective cohort study', *The Lancet*, vol. 0, no. 0, Feb. 2019.

374 [4] P. Cacoub *et al.*, 'Prognostic value of viral eradication for major adverse cardiovascular
375 events in hepatitis C cirrhotic patients', *Am. Heart J.*, vol. 198, pp. 4–17, Apr. 2018.

376 [5] M.-H. Lee *et al.*, 'Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic
377 and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study', *J. Infect.*
378 *Dis.*, vol. 206, no. 4, pp. 469–477, Aug. 2012.

379 [6] H. Razavi *et al.*, 'The present and future disease burden of hepatitis C virus (HCV)
380 infection with today's treatment paradigm', *J. Viral Hepat.*, vol. 21, no. s1, pp. 34–59,
381 2014.

382 [7] O. Keiser *et al.*, 'Trends in hepatitis C-related mortality in Switzerland', *J. Viral Hepat.*,
383 vol. 25, no. 2, pp. 152–160, Feb. 2018.

384 [8] K. N. Ly, J. Xing, R. M. Klevens, R. B. Jiles, J. W. Ward, and S. D. Holmberg, 'The Increasing
385 Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007',
386 *Ann. Intern. Med.*, vol. 156, no. 4, p. 271, Feb. 2012.

387 [9] R. Mahajan *et al.*, 'Mortality Among Persons in Care With Hepatitis C Virus Infection: The
388 Chronic Hepatitis Cohort Study (CHeCS), 2006–2010', *Clin. Infect. Dis.*, vol. 58, no. 8, pp.
389 1055–1061, Apr. 2014.
390 [10] L. I. Backus, P. S. Belperio, T. A. Shahoumian, and L. A. Mole, 'Direct-acting antiviral
391 sustained virologic response: Impact on mortality in patients without advanced liver
392 disease', *Hepatology*, vol. 68, no. 3, pp. 827–838, 2018.
393 [11] L. I. Backus, P. S. Belperio, T. A. Shahoumian, and L. A. Mole, 'Impact of Sustained
394 Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with
395 Advanced Liver Disease', *Hepatology*, vol. 69, no. 2, pp. 487–497, 2019.
396 [12] L. Prasad, V. M. Spicher, M. Zwahlen, M. Rickenbach, B. Helbling, and F. Negro,
397 'Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS)', *Int. J. Epidemiol.*, vol. 36, no.
398 4, pp. 731–737, Aug. 2007.
399 [13] 'ICD-10 Version:2016'. [Online]. Available: https://icd.who.int/browse10/2016/en.
400 [Accessed: 29-Nov-2019].
401 [14] M. L. McHugh, 'Interrater reliability: the kappa statistic', *Biochem. Medica*, vol. 22,
402 no. 3, pp. 276–282, Oct. 2012.
403 [15] H. Putter, 'Tutorial in biostatistics: Competing risks and multi-state models Analyses
404 using the mstate package', p. 43.
405 [16] L. D. Fisher and D. Y. Lin, 'Time-Dependent Covariates in the Cox Proportional-
406 Hazards Regression Model', *Annu. Rev. Public Health*, vol. 20, no. 1, pp. 145–157, 1999.
407 [17] T. Therneau, C. Crowson, and E. Atkinson, 'Using Time Dependent Covariates and
408 Time Dependent Coefficients in the Cox Model', p. 27.
409 [18] B. E. Shepherd and P. F. Rebeiro, 'Assessing and interpreting the association between
410 continuous covariates and outcomes in observational studies of HIV using splines', *J.
411 Acquir. Immune Defic. Syndr. 1999*, vol. 74, no. 3, pp. e60–e63, Mar. 2017.

[19] S. van Buuren and K. Groothuis-Oudshoorn, ‘mice: Multivariate Imputation by Chained Equations in R’, *J. Stat. Softw.*, vol. 45, no. 1, pp. 1–67, Dec. 2011.

[20] J.-F. Dufour, A. Bordoni, and M. Lorez, ‘Trends in Hepatic Cancer Survival in Switzerland’, *Bull. Suisse Cancer*, vol. éd. Mars, no. 1, pp. 46–50, 2014.

[21] Y. Wen, Y. X. Zheng, and D. M. Tan, ‘A Comprehensive Long-Term Prognosis of Chronic Hepatitis C Patients With Antiviral Therapy: A Meta-Analysis of Studies From 2008 to 2014’, *Hepat. Mon.*, vol. 15, no. 5, May 2015.

[22] M. Lu *et al.*, ‘Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma’, *J. Viral Hepat.*, vol. 23, no. 9, pp. 718–729, Sep. 2016.

[23] J. Fehr, D. Moradpour, A. Rauch, and B. Müllhaupt, ‘Treatment of Chronic Hepatitis C - September 2016 Update SASL-SSI Expert Opinion Statement’, p. 10.

[24] N. Vernaz *et al.*, ‘A buyers’ club to improve access to hepatitis C treatment for vulnerable populations’, *Swiss Med. Wkly.*, vol. 148, no. 3334, Aug. 2018.

[25] F. Cominetti, T. Simonson, F. Dubois-Arber, J.-P. Gervasoni, M. Schaub, and M. Monnat, ‘Analyse de la situation de l'hépatite C chez les usagers de drogue en Suisse’, 2015. .

[26] C. Zahnd, M. Brezzi, B. Bertisch, F. Giudici, and O. Keiser, ‘Analyse de situation des hépatites B et C en Suisse’. Sur mandat de l`Office fédéral de la santé publique (OFSP), 2017.

[27] F. Negro and L. Maistat, ‘Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from over’, *Swiss Med. Wkly.*, vol. 147, no. 4950, Dec. 2017.

435 # Tables

436

437 **Table 1 : Categories of causes of death**

Death cause group	Eligibility criteria
Liver failure (other than liver cancer)	Selected ICD-10 codes: B15 - B19 (viral hepatitis) B94.2 (sequelae of viral hepatitis) K70 (alcoholic liver disease) K71 - K77 (toxic/chronic/other liver disease) T86.4 (liver transplant failure and rejection) Z94.4 (liver transplant status) OR Death identified as physically related to HCV infection according to information obtained at or after a SCCS visit
Liver cancer	Selected ICD-10 code: C22
Non-liver cancer	Selected ICD-10 codes: C00 - C21, C23 - C97 (all malignant neoplasms except liver cancer, including leukaemia) D00 – D48 (all in-situ, benign and unknown neoplasms)
Unnatural cause	Selected ICD-10 codes: S00 - T88 except T86.4 (injury, poisoning and certain other consequences of external cause) V01 – Y98 (external causes of morbidity and mortality) Z92 – Z99 except Z94.4 (health-service-related factor) OR Death identified as due to accident, suicide or overdose of narcotics according to the SCCS
Cardiovascular	Selected ICD-10 codes: I00 – I99 (diseases of the circulatory system)
Other	All the deaths with selected ICD-10 code not entering any of the criteria described above
Unspecified	No selected ICD-10 code and no complementary information from the SCCS

438

439

Table 2: Characteristics of study participants at enrolment and causes of death in the Swiss Hepatitis C Cohort Study

P-values from Kruskal-Wallis rank sum test for continuous variables, and Chi-squared test for categorical variables are shown.

		All	Death	Death linked	Death not linked	P–value linked VS not linked
		N=4700	N=478	N=368	N=110	
Sex						P = 0.86
	Male	2901 (61.72)	338 (70.71)	259 (70.38)	79 (71.82)	
	Female	1799 (38.28)	140 (29.29)	109 (29.62)	31 (28.18)	
Nationality						P = 0.28
	Swiss	3456 (73.53)	372 (77.82)	291 (79.08)	81 (73.64)	
	Other	1235 (26.28)	106 (22.18)	77 (20.92)	29 (26.36)	
	Unknown	9 (0.19)	X	X	X	
Age at start (yr)		47.5 (40.6 – 55.1)	51.8 (44.5 – 60)	52 (45 – 60.1)	50.9 (43.3 – 57.2)	P = 0.31
Age at death census (yr)		53.5 (46.4 – 60.5)	56 (48.5 – 64.7)	56.3 (50.4 – 65.3)	53.6 (46.1 – 60)	P = 0.01
Time from start to death census (yr)		6.5 (2.2 – 9)	4 (2 – 6.5)	4.9 (2.9 – 6.8)	1.6 (0.6 – 3.5)	P < 0.001
Treatment before start						P = NA
	No	2910 (61.91)	263 (55.02)	194 (52.72)	69 (62.73)	
	DAA (IFN–free)	33 (0.7)	X	X	X	
	IFN–based	1757 (37.38)	215 (44.98)	174 (47.28)	41 (37.27)	
IDU before start						P = 0.78
	Never	1780 (37.87)	182 (38.08)	142 (38.59)	40 (36.36)	
	Ever	2578 (54.85)	263 (55.02)	201 (54.62)	62 (56.36)	
	Unknown	342 (7.28)	33 (6.9)	25 (6.79)	8 (7.27)	
Fibrosis score at start						P = 0.42
	F0, F1 or F2	2538 (54)	160 (33.47)	123 (33.42)	37 (33.64)	
	F3 or F4	1261 (26.83)	229 (47.91)	185 (50.27)	44 (40)	
	Unknown	901 (19.17)	89 (18.62)	60 (16.3)	29 (26.36)	
Treatment status before start						P = 0.12
	Never treated	2910 (61.91)	263 (55.02)	194 (52.72)	69 (62.73)	
	Treated with SVR	693 (14.74)	44 (9.21)	35 (9.51)	9 (8.18)	
	Treated with failure	941 (20.02)	144 (30.13)	119 (32.34)	25 (22.73)	
	Treated, outcome unknown	156 (3.32)	27 (5.65)	20 (5.43)	7 (6.36)	
BMI at start		24.1 (21.6 – 27.1)	24.9 (21.6 – 28.5)	24.8 (21.6 – 28.4)	25.7 (21.8 – 30.8)	P = 0.26
HIV co–infection at start						P = 0.24
	No	3204 (68.17)	326 (68.2)	252 (68.48)	74 (67.27)	
	Yes	258 (5.49)	51 (10.67)	35 (9.51)	16 (14.55)	
	Unknown	1238 (26.34)	101 (21.13)	81 (22.01)	20 (18.18)	
Cirrhosis at start						P = 0.84
	No	3259 (69.34)	213 (44.56)	165 (44.84)	48 (43.64)	
	Yes	828 (17.62)	207 (43.31)	163 (44.29)	44 (40)	
	Unknown	613 (13.04)	58 (12.13)	40 (10.87)	18 (16.36)	
Diabetes mellitus at start						P = 0.01
	No	4019 (85.51)	336 (70.29)	274 (74.46)	62 (56.36)	
	Yes	275 (5.85)	52 (10.88)	33 (8.97)	19 (17.27)	
	Unknown	406 (8.64)	90 (18.83)	61 (16.58)	29 (26.36)	
Alcohol consumption at start						P = 0.11
	Light	2952 (62.81)	268 (56.07)	199 (54.08)	69 (62.73)	
	Former	348 (7.4)	43 (9)	38 (10.33)	5 (4.55)	
	Heavy	749 (15.94)	111 (23.22)	91 (24.73)	20 (18.18)	
	Moderate	563 (11.98)	46 (9.62)	34 (9.24)	12 (10.91)	
	Unknown	88 (1.87)	10 (2.09)	6 (1.63)	4 (3.64)	
Cause of death						P = NA
	Cardiovascular	33 (0.7)	33 (6.9)	26 (7.07)	7 (6.36)	
	Liver cancer	89 (1.89)	89 (18.62)	84 (22.83)	5 (4.55)	
	Liver failure	114 (2.43)	114 (23.85)	99 (26.9)	15 (13.64)	
	Non–liver cancer	72 (1.53)	72 (15.06)	65 (17.66)	7 (6.36)	
	Other	59 (1.26)	59 (12.34)	41 (11.14)	18 (16.36)	
	Unnatural	65 (1.38)	65 (13.6)	53 (14.4)	12 (10.91)	

Table 3: Estimates of the effect of gender, age, treatment, fibrosis stage and IDU on mortality, from Cox regression models, accounting for competing risk

A) For all-cause mortality; B) For cause-specific mortality

A)

	Total: 4700 persons	All–cause (478 deaths)
Sex		P < 0.001
	Male	1
	Female	0.68 (0.56 – 0.84)
Age at start (yr)		P < 0.001
	20	0.59 (0.37 – 0.96)
	40	1
	60	2.52 (2.04 – 3.11)
Treatment status		P < 0.001
	Never treated	1
	Treated with DAA, SVR	0.23 (0.08 – 0.63)
	Treated with DAA, failure	0.94 (0.33 – 2.66)
	Treated with IFN, SVR	0.33 (0.24 – 0.45)
	Treated with IFN, failure	0.87 (0.71 – 1.07)
Fibrosis score		P < 0.001
	F0, F1 or F2	1
	F3 or F4	3.57 (2.9 – 4.38)
IDU		P < 0.001
	Never	1
	Ever	2.01 (1.57 – 2.58)

B)

	Total: 4700 persons	Liver failure (114 deaths, 23.8%)	Liver cancer (89 deaths, 18.6%)	Non–liver cancer (72 deaths, 15.1%)	Cardiovascular (33 deaths, 6.9%)	Unnatural cause (65 deaths, 13.6%)
Sex		P = 0.15	P = 0.09	P = 0.074	P = 0.041	P = 0.18
	Male	1	1	1	1	1
	Female	0.73 (0.48 – 1.12)	0.66 (0.41 – 1.07)	0.61 (0.36 – 1.05)	0.44 (0.2 – 0.97)	0.68 (0.39 – 1.19)
Age at start (yr)		P = 0.016	P < 0.001	P < 0.001	P < 0.001	P = 0.044
	20	0.26 (0.08 – 0.89)	0.08 (0.01 – 0.62)	0.05 (0.01 – 0.28)	0.65 (0.08 – 5.62)	2.92 (1.23 – 6.96)
	40	1	1	1	1	1
	60	2.1 (1.27 – 3.48)	6.32 (2.74 – 14.57)	8.5 (4.03 – 17.92)	5.23 (2.05 – 13.31)	1.04 (0.59 – 1.84)
Treatment status		P < 0.001	P < 0.001	P = 0.29	P = 0.16	P = 0.12
	Never treated	1	1	1	1	1
	Treated with SVR	0.18 (0.08 – 0.38)	0.32 (0.15 – 0.7)	0.6 (0.32 – 1.14)	0.39 (0.14 – 1.11)	0.47 (0.23 – 0.97)
	Treated with failure	0.8 (0.53 – 1.2)	1.37 (0.83 – 2.26)	0.83 (0.46 – 1.5)	0.62 (0.26 – 1.45)	0.92 (0.5 – 1.7)
Fibrosis score		P < 0.001	P < 0.001	P = 0.11	P = 0.0064	P = 0.024
	F0, F1 or F2	1	1	1	1	1
	F3 or F4	12.67 (7.22 – 22.24)	13.75 (6.49 – 29.17)	1.51 (0.91 – 2.51)	2.91 (1.35 – 6.27)	1.96 (1.09 – 3.5)
IDU		P = 0.25	P = 0.19	P < 0.001	P = 0.2	P = 0.0013
	Never	1	1	1	1	1
	Ever	1.32 (0.82 – 2.11)	1.47 (0.83 – 2.62)	3.33 (1.68 – 6.6)	2.01 (0.7 – 5.78)	3.57 (1.64 – 7.77)

457 # Figure legends

458 **Fig. 1. Flow chart illustrating the linkage between the Swiss Hepatitis C Cohort Study (SCCS)**
459 **and the death registry of the Swiss Federal Office of Statistics (SFSO)**

460 **Fig. 2. Crude mortality rates over the years for all-cause mortality, liver failure and liver**
461 **cancer mortality in the Swiss Hepatitis C Cohort Study**

462 **Fig. 3. Cumulative incidence of different causes of death since registration into the Swiss**
463 **Hepatitis C cohort study (causes of death are in the same order in the legend and on the**
464 **plot)**

465 # Figures

466 **Fig. 1.**



467

468

469 **Fig. 2**

470



471

472

473 **Fig. 3**



474

Appendix

Appendix 1: Details on the multiple imputation

Because adding variables that are not part of the analysis can improve the imputation, we added the following baseline explanatory variables: body mass index (BMI), HIV co-infection, cirrhotic status, diabetes comorbidity, alcohol consumption (light/no drinker if average consumption ≤ 20g/day, moderate drinker if average consumption between 21 and 40g/day, excessive drinker if average consumption > 40g/day, and former drinker if ever drank more than 40g/day but is now a light or moderate drinker). Furthermore, the outcome was also included in the imputation. We ran the model on 20 imputed datasets for each analysis and combined the estimates with Rubin's rule.

484 **Appendix 2: Time trends in mortality rates (with 95% confidence intervals), per cause of death**

485 The x-axis corresponds to the year of death



486

Appendix 3 : Hazard ratios from Cox regression models, accounting for competing risk, excluding persons with missing information (sensitivity analysis)

A) For all-cause mortality ; B) For cause-specific mortality

A)

	Total: 4700 persons	All–cause (294 deaths)
Sex		P < 0.001
	Male	1
	Female	0.63 (0.49 – 0.82)
Age at start (yr)		P < 0.001
	20	0.43 (0.22 – 0.85)
	40	1
	60	2.81 (2.09 – 3.78)
Treatment status		P < 0.001
	Never treated	1
	Treated with DAA, SVR	0.13 (0.03 – 0.52)
	Treated with DAA, failure	0.3 (0.04 – 2.19)
	Treated with IFN, SVR	0.32 (0.23 – 0.46)
	Treated with IFN, failure	0.78 (0.59 – 1.01)
Fibrosis score		P < 0.001
	F0, F1 or F2	1
	F3 or F4	3.48 (2.7 – 4.49)
IDU		P < 0.001
	Never	1
	Ever	1.98 (1.46 – 2.68)

B)

	Total: 2719 persons	Liver failure (80 deaths, 27.2%)	Liver cancer (60 deaths, 20.4%)	Non–liver cancer (47 deaths, 16%)	Cardiovascular (20 deaths, 6.8%)	Unnatural cause (28 deaths, 9.5%)
Sex		P = 0.66	P = 0.0075	P = 0.068	P = 0.026	P = 0.53
	Male	1	1	1	1	1
	Female	0.9 (0.55 – 1.46)	0.42 (0.22 – 0.79)	0.53 (0.27 – 1.05)	0.28 (0.09 – 0.86)	0.77 (0.33 – 1.76)
Age at start (yr)		P = 0.12	P < 0.001	P < 0.001	P < 0.001	P = 0.72
	20	0.25 (0.06 – 1.16)	0.16 (0.02 – 1.61)	0.15 (0.02 – 1.01)	0.75 (0.05 – 11.65)	1.69 (0.38 – 7.54)
	40	1	1	1	1	1
	60	1.95 (1.03 – 3.7)	5.51 (2.06 – 14.72)	6.75 (2.94 – 15.47)	3.87 (1.17 – 12.84)	0.77 (0.28 – 2.13)
Treatment status		P < 0.001	P < 0.001	P = 0.63	P = 0.18	P = 0.74
	Never treated	1	1	1	1	1
	Treated with SVR	0.09 (0.03 – 0.23)	0.38 (0.15 – 0.95)	0.7 (0.34 – 1.45)	0.44 (0.14 – 1.35)	0.7 (0.27 – 1.8)
	Treated with failure	0.53 (0.33 – 0.86)	1.71 (0.87 – 3.37)	0.87 (0.43 – 1.77)	0.39 (0.13 – 1.22)	0.93 (0.37 – 2.38)
Fibrosis score		P < 0.001	P < 0.001	P = 0.85	P = 0.14	P = 0.21
	F0, F1 or F2	1	1	1	1	1
	F3 or F4	18.28 (8.9 – 37.58)	10.84 (4.84 – 24.26)	1.06 (0.57 – 1.95)	2 (0.79 – 5.04)	1.69 (0.74 – 3.83)
IDU		P = 0.53	P = 0.12	P < 0.001	P = 0.8	P = 0.02
	Never	1	1	1	1	1
	Ever	1.19 (0.69 – 2.04)	1.72 (0.88 – 3.4)	4.39 (1.9 – 10.14)	0.84 (0.23 – 3.14)	3.75 (1.23 – 11.42)

495 **Appendix 4: Comparison between SCCS and SFSO death cause groups**

SCCS / SFSO	Cardiovascular	Liver cancer	Liver failure	Non−liver cancer	Other	Unnatural cause
Cardiovascular	9	2	9	3	3	1
Liver cancer	0	34	1	2	0	0
Liver failure	3	22	34	2	7	1
Non−liver cancer	0	2	1	33	0	0
Other	6	6	21	12	14	3
Overdose	1	0	0	0	1	5
Unnatural cause	0	0	0	0	2	9
Unspecified	10	13	24	15	29	28

496